Head & Neck Cancers

Following treatment with single-agent nivolumab (Opdivo), patients with head and neck squamous cell carcinoma saw improved or stable quality of life scores.

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses a phase II study investigating induction chemotherapy and transoral surgery for patients with head and neck cancer.

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the treatment for patients with HPV-associated head and neck cancer.

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the adverse events (AEs) associated with radiation therapy (RT) for patients with oropharyngeal squamous cell carcinomas.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses challenges still facing the field of head and neck cancer and ongoing trials with a goal to improve patient outcomes.

Robert Ferris, MD, PhD, discusses the RTOG 3504 trial, as well as the utility of immunotherapy agents for patients with intermediate and high-risk head and neck squamous cell carcinoma.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the safety profile of the RTOG 3504 trial for patients with head and neck cancer.

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses pembrolizumab (Keytruda) in patients with head and neck cancer.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the rationale for combining radiation therapy with immunotherapy for the treatment of patients with head and neck cancer.

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.

Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the combination of a PD-L1 inhibitor to the standard of care for patients with head and neck cancer.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses immunotherapy in patients with locally advanced head and neck cancer.

Lenvatinib (Lenvima) significantly improved overall survival in patients older than 65 years with radioiodine-refractory differentiated thyroid cancer.

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses an ongoing clinical trial of pembrolizumab (Keytruda) combined with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the impact of immunotherapy in head and neck cancer.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the RTOG 3504 study in head and neck cancer.

The combination of the IDO inhibitor epacadostat and nivolumab demonstrated promising signs of activity for patients with squamous cell carcinoma of the head and neck and those with melanoma.

An analysis in locally advanced squamous cell carcinoma of the head and neck showed that weekly low-dose schedules of chemoradiotherapy produce comparable survival outcomes and response rates as the standard 3-weekly schedule.

Dhanya K. Nambiar, PhD, Stanford University, discusses the detection of Galectin-1 for patients with head and neck cancer.

Iain Morgan, PhD, discusses research that redefines HPV-positive head and neck cancer and may also identify new therapeutic targets.

Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.